优思明品牌怎么样 申请店铺

外推网助力优思明品牌出海！通过在本页面挂载优思明品牌的产品链接和联系邮箱，可以提高优思明产品曝光！跨境电商爆单神器，目前只要100元/年哦~

优思明，由先灵公司开发的新型独特的孕激素屈螺酮（Drospirenone），在提供可靠避孕的同时，还附有其他的好处。屈螺酮(Drospirenone)另外一个作用可抵抗盐皮质激素的作用。优思明尤其被女性喜爱的是它有效降低了因雌激素引起的水分潴留（防止体重增加，乳房胀痛，乳房/腹部鼓胀）。而且，屈螺酮（drospirenone）的抗雄作用可显著改善皮肤和毛发问题。

拜耳医药保健

拜耳医药保健是拜耳集团的子公司，总部位于德国勒沃库森，是一家在世界医药保健领域内居领先地位的创新型医药公司。公司在全球范围内经营动物保健、保健消费品、糖尿病保健和处方药等业务。拜耳医药保健的目标是在全球发现并生产可以促进人类和动物健康的产品。

拜耳处方药部

2006年并购先灵公司是拜耳历史上最大的一起收购案。之后组成的拜耳处方药，一家在全球制药专业领域排名前十的强大而领先的公司，在生物学领域占有举足轻重的地位。 

拜耳处方药关注于四个战略性业务领域：影像诊断、普药、特殊治疗和女性健康。

拜耳医疗保健事业群-西药部在全球超过100多国设立子公司，产品遍及全球100多个国家，2010年的业绩更达到近110亿欧元。此外，拜耳医疗保健事业群-西药部的全球员工人数达38,000人，其中超过6,200人为研发人员。

拜耳医疗保健事业群-处方药(BayerHealthCarePharmaceuticals)为拜耳医疗保健公司(BayerHealthCareAG)旗下众多的部门之一，拜耳医疗保健事业研发重点领域为肿瘤医学、女性医疗保健、心脏学及血液学及诊断用显影剂。

为了使产品成功地促进人类的生活质量，我们致力于研发创新性的药品及医疗保健等相关服务，同时，持续增进既有产品的效能与表现。在这样的理念之下，拜耳医疗保健事业群-西药部可充分运用过去一百多年的产业经验，为人类缔造更健康、更美好的未来。

拜耳医疗保健事业群-西药部着重于以下五大医疗保健领域的研究，并且缔造卓越贡献：

心脏医学及血液学(Cardiovascularandblooddiseases)

肿瘤医学(Oncologicaldiseases)

眼科医学(Ophthalmology)

女性医疗保健(Women'shealthcare)

诊断用显影剂(Imagingtechniques)

拜耳处方药部发展历程

2011拜耳先灵西药部正式更名为"拜耳医疗保健事业群-处方药部".

2010为了持续与重大疾病，如：癌症奋战，拜耳医疗保健事业群正于德国的乌帕塔(Wuppertal)建造一座专门研发生物科技为主的制药中心。

2009一群来自拜耳先灵西药部的研发团队在2009年因开发出新型的抗凝药物而赢得“GermanFuturePrize”大奖。

2009拜耳先灵西药部为拓展自己在全球研究发展上的能耐，将在往后五年投资1亿欧元建造位于中国北京的"全球研发中心"。

2009Qlaira®，第一款含雌二醇(与女性身体产生的雌激素相同)的新型口服避孕药，现已于一些欧洲国家上市。

2008排挤性收购少数拜耳先灵西药部(BayerScheringPharmaAG)剩余股东的效果于2008年9月开始出现成效，2008至2009年间，拜耳现有的西药部门与位于德国柏林的拜耳先灵西药部合而为一，正式成为一个独立的拜耳子集团。

2007年1月，拜耳先灵西药部股东特别大会决定采用「排挤性收购」剩余的少数股东。总部设于柏林的拜耳先灵西药部，与拜耳现有的西药部门联合营运，成为拜耳医疗保健事业群的部门之一。

2007口服抗癌药物蕾莎瓦®(Nexavar®)于美国取得治疗肝癌的许可。

2006年12月29日，公司正式更名为“拜耳先灵医药股份有限公司”，总部设于德国柏林。

2006拜耳公开宣布收购德国柏林的先灵公司(ScheringAG）。同年7月，先灵一亿九千一百万流通在外的股票中，拜耳共收购了92.4%。12月，先灵公司正式更名为"拜耳先灵西药部"。
……

1871年10月23号，恩斯特．先灵(ErnstScering)将他的制药厂企业化，成立有限公司，并取名为"PCL化学工厂"(E.Schering的前身)

1863染料商人富黎德里希．拜耳（FriedrichBayer）和染料师傅约翰．富黎德里希．威斯考特（JohannFriedrichWeskott）合伙于1863年8月1日在今日德国的乌帕塔市（Wuppertal）巴门（Barmen）行政区创立「富黎德里希拜耳公司」（Friedr.Bayeretcomp.），从事合成染料制造与销售事业。

公元1851年，恩斯特．先灵(ErnstScering)在柏林买下了一家化学药品店，并将它改名为"绿色药局"(GreenPharmacy)，从此开启了先灵在制药业中的历史。

Yosmin, a new and unique progesterone developed by Schering, provides reliable contraception with other benefits. Another effect of drospironone is to resist the action of corticosteroids. What the woman likes is that it effectively reduces the retention of water due to estrogen (to prevent weight gain, breast distention, breast / abdominal bulge *). Moreover, drospirenone can significantly improve skin and hair problems. Bayer healthcare Bayer healthcare is a subsidiary of Bayer Group, headquartered in Leverkusen, Germany. It is a leading innovative pharmaceutical company in the field of healthcare in the world. The company is engaged in animal health care, health consumer goods, diabetes health care and prescription medicine business all over the world. The goal of Bayer healthcare is to discover and produce products around the world that can promote human and animal health. The acquisition of Schering by Bayer prescription medicine in 2006 is the largest acquisition in Bayer's history. Bayer prescription medicine, a powerful and leading company in the top ten pharmaceutical professional fields in the world, plays an important role in the field of biology. Bayer prescription drugs focuses on four strategic business areas: imaging diagnosis, general medicine, special treatment and women's health. Bayer health care business group - Western Medicine Department has set up subsidiaries in more than 100 countries around the world, with products in more than 100 countries around the world, and its performance in 2010 reached nearly 11 billion euros. In addition, the Bayer healthcare business group - Western Medicine Department has 38000 employees worldwide, more than 6200 of whom are R & D personnel. Bayer healthcare pharmaceuticals is one of the many departments of Bayer healthcare AG. The research and development focus of Bayer healthcare is oncology, female healthcare, cardiology, hematology and diagnostic developer. In order to make the products successfully promote the quality of human life, we are committed to the research and development of innovative drugs, medical care and other related services, while continuously improving the efficiency and performance of existing products. Under such a concept, Bayer medical and health business group western medicine department can make full use of the industrial experience of the past 100 years to create a healthier and better future for mankind. Bayer healthcare business group - Western medicine department focuses on the following five areas of healthcare research, and creates outstanding contributions: cardiology and hematology, oncology, ophthalmology, women's health care, diagnostic imaging technologies, Bayer prescription medicine department, 2011 Bayer first In 2010, in order to continue to fight against major diseases, such as cancer, Bayer healthcare group is building a pharmaceutical center specializing in research and development of biotechnology in Wuppertal, Germany. In 2009, a group of R & D teams from Bayer Schering western medicine department won the "germanfutureprize" award for developing new anticoagulants. In 2009, Bayer Schering western medicine department will invest 100 million euros to build a "global R & D center" in Beijing, China, in order to expand its ability in global research and development. 2009qlaira ®, the first new oral contraceptive containing estradiol (the same estrogen produced by women's bodies), is now available in some European countries. In 2008, the effect of crowding out a small number of remaining shareholders of Bayer Schering Pharma Ag began to take effect in September 2008. From 2008 to 2009, Bayer's existing western medicine department and Bayer Schering Pharma Ag in Berlin, Germany, were integrated into one, officially becoming an independent Bayer subsidiary group. In January 2007, the shareholders' special meeting of Bayer Schering western medicine decided to adopt the "crowding out acquisition" of the remaining minority shareholders. The Bayer Schering western medicine department, headquartered in Berlin, operates jointly with Bayer's existing western medicine department and becomes one of the departments of Bayer's healthcare business group. In 2007, the oral anticancer drug Nexavar ® was licensed in the United States for the treatment of liver cancer. On December 29, 2006, the company officially changed its name to Bayer Schering Pharmaceutical Co., Ltd., with its headquarters in Berlin, Germany. In 2006, Bayer announced its acquisition of Schering AG in Berlin, Germany. In July of the same year, Bayer acquired 92.4% of Schering's 191 million outstanding shares. In December, Schering officially changed its name to "Bayer Schering western medicine department" On October 23, 1871, Ernst Schering incorporated his pharmaceutical factory into a limited company and named it "PCL chemical factory" (the predecessor of e.schering). 1863, Friedrich Bayer, a dyestuff merchant, and Johann Friedrich weskott, a dyestuff master, cooperated on August 1, 1863 in today's wupata, Germany (Wuppertal) Barmen Administrative Region founded friedr. Bayeretcomp., which is engaged in the manufacturing and sales of synthetic dyes. In 1851, Ernst Schering bought a chemical store in Berlin and renamed it "Green Pharmacy", which opened Schering's history in the pharmaceutical industry.

本文链接： https://brand.waitui.com/693cf1987.html 联系电话：请联系客服添加